CHARACTERISTICS AND CLINICAL OUTCOMES IN PATIENTS WITH CIRRHOSIS DUE TO METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN SWEDEN

被引：0
|
作者：
Shang, Ying [1 ]
Zhang, Xiao [2 ]
Fernandes, Gail [2 ]
Melaragno, Matthew [2 ]
Engel, Samuel [2 ]
Vessby, Johan [3 ]
Ekstedt, Mattias [4 ]
Hagstrom, Hannes [1 ]
机构：
[1] Karolinska Inst, Stockholm, Sweden
[2] Merck & Co Inc, Rahway, NJ USA
[3] Uppsala Univ Hosp, Uppsala, Sweden
[4] Linkoping Univ, Linkoping, Sweden
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1085
引用
收藏
页码：S821 / S822
页数：2
相关论文
共 50 条
  • [21] Subclinical myocardial fibrosis is related to disease severity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
    Nabilou, Puria
    Wiese, Signe
    Hetland, Liv
    Werge, Mikkel
    Thing, Mira
    Rashu, Elias
    Junker, Anders
    Barlose, Mads
    Siebner, Hartwig
    Moller, Soren
    Bendtsen, Flemming
    Gluud, Lise Lotte
    Hove, Jens
    JOURNAL OF HEPATOLOGY, 2024, 80 : S555 - S555
  • [22] Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
    Nakamura, Toru
    Masuda, Atsutaka
    Nakano, Dan
    Amano, Keisuke
    Sano, Tomoya
    Nakano, Masahito
    Kawaguchi, Takumi
    CELLS, 2025, 14 (06)
  • [23] Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ali, Sajjadh M. J.
    Lai, Michelle
    ANNALS OF INTERNAL MEDICINE, 2025, 178 (01) : ITC1 - ITC17
  • [24] Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis A Randomized Clinical Trial
    Simon, Tracey G.
    Wilechansky, Robert M.
    Stoyanova, Stefania
    Grossman, Alessandra
    Dichtel, Laura E.
    Lauer, Georg M.
    Miller, Karen K.
    Hoshida, Yujin
    Corey, Kathleen E.
    Loomba, Rohit
    Chung, Raymond T.
    Chan, Andrew T.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (11): : 920 - 929
  • [25] Thyroid Hormone and Mitochondrial Dysfunction: Therapeutic Implications for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Ramanathan, Raghu
    Patwa, Sohum A.
    Ali, Ahmad Hassan
    Ibdah, Jamal A.
    CELLS, 2023, 12 (24)
  • [26] Converging Pathways between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Diabetes in Children
    Faienza, Maria Felicia
    Farella, Ilaria
    Khalil, Mohamad
    Portincasa, Piero
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (18)
  • [27] THE PROGNOSTIC ROLE OF THE ELF TEST, COMPARED TO LIVER BIOPSY, IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
    Liguori, A.
    D'Ambrosio, F.
    Nicholas, V.
    Termite, F.
    Petrucci, L.
    Beschi, R.
    Orienti, M.
    Galletti, S.
    Cardinali, S.
    Riccardi, L.
    Pizzolante, F.
    De, Matthaeis N.
    Zocco, M. A.
    Giustiniani, M. C.
    Marrone, G.
    Biolato, M.
    Cefalo, C.
    Vecchio, F. M.
    Pompili, M.
    Rapaccini, G. L.
    Grieco, A.
    Urbani, A.
    Sanguinetti, M.
    Gasbarrini, A.
    Miele, L.
    DIGESTIVE AND LIVER DISEASE, 2024, 56 : S257 - S257
  • [28] Genome-wide Association Study on Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
    Darlay, Rebecca
    Zatorska, Michalina
    Worthington, Sarah
    Anstee, Quentin M.
    Daly, Ann K.
    Cordell, Heather J.
    GENETIC EPIDEMIOLOGY, 2024, 48 (07) : 352 - 352
  • [29] Epidemiology of metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD)
    Wong, Robert J.
    METABOLISM AND TARGET ORGAN DAMAGE, 2024, 4 (04):
  • [30] Cutting edge: ferroptosis in metabolic dysfunction-associated steatotic liver disease (MASLD) pathogenesis and therapy
    El-Sehrawy, Amr Ali Mohamed Abdelgawwad
    Rashid, Teeba Ammar
    Ullah, Muhammad Ikram
    Uthirapathy, Subasini
    Ganesan, Subbulakshmi
    Singh, Abhayveer
    Devi, Anita
    Joshi, Kamal Kant
    Jasim, Ahmed Salman
    Kadhim, Abed J.
    FUNCTIONAL & INTEGRATIVE GENOMICS, 2025, 25 (01)
12345